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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.12.004BACKGROUND: Response to hydroxyurea therapy in homozygous or compound heterozygous beta thalassae-
mia (BT) has been reported as more favourable in the presence of XmnI polymorphism. The prevalence of XmnI
polymorphism may vary with BT phenotypes and genotypes, and differs geographically in distribution. Preva-
lence of XmnI polymorphism is not known in northern Pakistan.
OBJECTIVE: To determine the frequency of Gc-globin promoter 158 (C>T) XmnI polymorphism (XmnI poly-
morphism) in patients with homozygous or compound heterozygous beta thalassaemia.
MATERIALS: Polymerase chain reaction (PCR) for common beta thalassaemia mutations and Gc-globin pro-
moter 158 (C>T) XmnI polymorphism was performed on 107 blood samples of transfusion dependent beta
thalassaemia (BT) patients in Pakistan. One hundred samples of unrelated BT traits and 94 samples of healthy
subjects as controls were also analysed for BT mutations and XmnI polymorphism.
RESULTS: Out of 301 DNA samples, XmnI polymorphism was detected in 71(24%); in normal controls, XmnI
polymorphism was detected in 34/94 (36%) subjects; while in homozygous/compound heterozygous BT, it was
detected in 14/107(13%) patients (Fisher’s exact test, p = .0002). In heterozygous BT group, XmnI polymorphism
was detected in 23/100 subjects (Fisher’s exact test, p = .03 with normal controls, and p = .049 with homozy-
gous/compound heterozygous BT). The most common BT genotype was Frame Shift (Fr) 8–9/Fr 8–9, and none of
the patients with this genotype had XmnI polymorphism. The second most common genotype was IVSI-5/IVSI-5;
4/26 (15%). Cases with this genotype had XmnI polymorphism.
CONCLUSION: XmnI polymorphism in homozygous/compound heterozygous BT group is 13%. The most
common genotype associated with XmnI polymorphism was IVSI-5/IVSI-5.
KEYWORDS: Beta thalassemia; Hbf; Hydroxyurea; Xmn 1Gc polymorphismBeta thalassaemia is one of the major healthproblems in Pakistan. About 5% of the coun-try’s population are carriers of this genetic dis-
order.1 Patients with beta thalassaemia major (BTM)
require lifelong blood transfusions unless cured with
stem cell transplant or gene therapy. The prevalence
of beta thalassaemia (BT) mutations varies among dif-
ferent ethnic groups in Pakistan. The ﬁve commongenetic defects comprising IVS-1–5 (GﬁC), Fr 8/9
(+G), Fr 41/42 (-TTCT), IVS-1-1 (GﬁT) and
Del 619 cover 90% of BT in southern Pakistan, while
Cd 15 (G-A), Cd 5 (-CT), and IVSI-1 (G-T) are also
frequently detected among Punjabis and Pathans in
northern Pakistan.2,3 Genetic defects covering >90%
of BT in Pakistan cause transfusion dependent
anaemia.4arter 2015
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It is known that coinheritance of genetic factors
like C>T polymorphism at 158 base pair upstream
Gc gene (XmnI polymorphism) may affect the hae-
moglobin F (HbF) production in patients with
BTM or thalassaemia intermedia (TI).5,6 In condi-
tions of erythropoietic stress, as occurs in BTM, the
presence of XmnI polymorphism may activate pro-
duction of HbF, leading to amelioration of the pheno-
type.7 Hydroxyurea (HU) promotes HbF production
via reactivation of c-genes. It also suppresses the b
globin expression through its cytotoxic effects, which
may ameliorate the effects of the alpha/non alpha
chain imbalance.8 The response to hydroxyurea ther-
apy has been reported as more favourable in the pres-
ence of XmnI polymorphism, though this association
has not been well established.7,9 The prevalence of
XmnI polymorphism may vary with BT phenotypes
and with geographical distribution.10–12 The aim of
our study is to determine the frequency of XmnI
polymorphism in patients with homozygous/com-
pound heterozygous beta thalassaemia in our patient
population.MATERIALS AND METHODS
Polymerase chain reaction (PCR) for common beta
thalassaemia mutations and Gc-globin promoter
158 (C>T) XmnI polymorphism was performed
on 107 blood samples of transfusion-dependent BT
patients in Pakistan. One hundred samples of unre-
lated BT trait, and 94 samples of healthy subjects as
controls were also analysed for BT mutations and
XmnI polymorphism. The study was approved by
the ethical committee of the institute. Blood samples
were collected in ethylene-diamine-tetra-acetic-acid
(EDTA) vacutainers, and DNA was extracted from
peripheral blood using phenol–chloroform DNA
extraction method.
Beta thalassaemia mutations/deletions
PCR for BT mutations/deletions was performed by
multiplex ampliﬁcation refractory mutation system
(ARMS) in three separate reaction mixtures. The ﬁrst
multiplex contained primers (Invitrogen life technolo-
gies USA) for IVSI-5 (G-C), Fr 8–9 (+G), Fr 41-42
(-TTCT), IVSI-1 (G-T) and Del 619 bp. The sec-
ond multiplex contained primers for Cd 5 (-CT), Fr
16(-C), IVSI-1 (G-T), Cd30 (G-C), Cd 30 (G-A),
and IVSII-1 (G-A). The third multiplex contained
primers for Cd 15 (G-A) and Cap +1 (A-C). These
genotypes cover almost 98% of beta thalassaemia
mutations/deletions in Pakistan. PCR was performed
in a 25 ll reaction mixture containing 5 pmol of pre-Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015viously described set of primers, 0.3 units of Taq
polymerase (Fermentas Life Sciences, Vilnius, Lithu-
ania), 30 lM of each dNTP, (Fermentas Life Sci-
ences, Vilnius, Lithuania), 10 mmol Tris HCl (pH
8.3), 50 mmol KCl, 1.5 mmol MgCl2, 100 lg/ml gel-
atin and 0.3–0.5 lg of genomic DNA. The PCR pro-
cess consisted of 25 cycles of denaturation at 94 C
for one minute, primer annealing at 65 C for one
minute, and DNA extension reaction at 72 C for
1.5 min. In the ﬁnal cycle, the extension reaction
was prolonged to three minutes. The results were read
after 5% mini-polyacrylamide gel electrophoresis
(PAGE) and staining by silver nitrate. Where single
mutation was detected, a second PCR was run with
a set of primers containing the normal allele of the
respective mutation to detect the presence of normal
(wild type) sequence. Where the normal allele was
also ampliﬁed, the DNA in question was assigned
as heterozygous. Where the normal counterpart was
not detected, DNA was assigned as homozygous for
the respective mutation.
XmnI polymorphism
A restricted fragment length polymorphism (RFLP)
PCR was performed using the previously described
set of primers F50-GAACTTAAGAGATAATGGC
CTAA and R50-ATGACCCATGGCGTCTGGA
CTAG (Fermentas Life Sciences, Vilnius, Lithuania)
that ampliﬁed 641-bp fragment of DNA ﬂanking the
C–T polymorphism at 158 to the Gc-gene. PCR
was carried out in a 25 ll reaction mixture containing
5 pmol of primers, 0.3 units of Taq polymerase (Fer-
mentas Life Sciences, Vilnius, Lithuania), 30 lM of
each dNTP, (Fermentas Life Sciences, Vilnius, Lith-
uania), 10 mmol Tris HCl (pH 8.3), 50 mmol KCl,
1.5 mmol MgCl2, 100 lg/ml gelatin and 0.3–0.5 lg
of genomic DNA. Thermal cycling consisted of 25
cycles of denaturation at 94 C for 30 s, primer
annealing at 60 C for one minute and DNA exten-
sion reaction at 72 C for 1.5 min. In the ﬁnal cycle,
the extension reaction was prolonged to three min-
utes. The ampliﬁed fragments were digested overnight
at 37 C with 10 units of PdmI (XmnI) restriction
enzyme (Fermentas Life Sciences, Vilnius, Lithuania).
The results were read after running 5% PAGE and
staining by silver nitrate. Where the digested product
contained only 641 bp fragment, the / genotype
was assigned; where 641 bp, 418 bp and 223 bp were
detected, the +/ genotype was assigned. Where the
digested product contained 418 bp and 223 bp frag-
ments, the +/+ genotype was assigned (Figure 1).
Data was collected for statistical analysis using
SPSS 19 version. Fisher’s exact test was applied to11
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Figure 1. PCR for XmnI polymorphism, polyacrylamide gel electrophoresis and staining by silver nitrate showing patterns of normal, enzyme
digested and undigested amplified products. 1, Normal control; 2, XmnI -/-; 3, XmnI +/+; 4, Un-cut.
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between the groups. A p value <0.05 was taken as
signiﬁcant.RESULTS
Out of 301 DNA samples, XmnI polymorphism was
detected in 71(24%); in normal controls, XmnI poly-
morphism was detected in 34/94 (36%); while in
homozygous/compound heterozygous, BT XmnI
polymorphism was detected in 14/107(13%) patients
(Fisher’s exact test, p = .0002). In heterozygous BT
group XmnI polymorphism was detected in 23/100
subjects (Fisher’s exact test, p = .03 with normal con-
trols, and p = .049 with homozygous/compound het-
erozygous BT). Frequency of XmnI polymorphism in
all three groups is summarised in Table 1.Table 1. Frequency of XmnI polymorphism in controls with normal BT
heterozygous BT.
XmnI status Normal genotype Heteroz
/ 60 (64%) 77
/+ 32 (34%) 15
+/+ 2 (2%) 8
94 1
BT, Beta thalassaemia; XmnI, Gc-globin promoter 158 (C>T) XmnI polymorphism.All patients with homozygous/compound hetero-
zygous BT (n = 107) were transfusion-dependent,
between six months to 31 years of age, mean
6 + 5 years). Sixty-three (59%) were male and
44(41%) were females. XmnI polymorphism was
detected in 14 (13%) patients; 5/14 were heterozy-
gous, and 9/14 were homozygous for XmnI polymor-
phism. Mean age of those with XmnI polymorphism
was 8 years +7.9, while mean age of those without
XmnI polymorphism was 5.8 + 4.5, (Un-paired t-
test, p = .15). XmnI polymorphism was equally dis-
tributed in bo/bo (5/14, 35.5%) phenotype, and in
b+/b+(5/14, 35.5%) phenotype, while in bo/b+ it
was less common than the above two groups (4/14,
29.0%). The most common BT genotype was Fr 8-
9/Fr 8-9, and none of the patients with this genotype
had XmnI polymorphism. The second most commongenotype, heterozygous BT, and cases with homozygous/compound
ygous BT Homozygous/compound heterozygous BT
(77%) 93 (87%)
(15%) 5 (5%)
(8%) 9 (8%)
00 107
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Table 2. Frequency of XmnI polymorphism in homozygous/compound heterozygous BT.
*Genotype XmnI / XmnI /+ XmnI +/+ Total
Fr 8-9 44 (40%) 0 0 44 (40%)
IVS 1–5 30 (28%) 5 (5%) 4 (4%) 39 (36%)
Fr 41-42 3 (3%) 0 1 (1%) 4 (4%)
Fr 16 2 (2%) 0 0 2 (2%)
Cd 5 7 (7%) 0 1 (1%) 8 (8%)
Cd 15 7 (7%) 0 1 (1%) 8 (8%)
Cd 30 0 0 1 (1%) 1 (1%)
IVSII-1 0 0 1 (1%) 1 (1%)
Total 93 (86%) 5 (5%) 9 (9%) 107 (100%)
BT: Beta thalassaemia.
*Genotype, Homozygous or compound heterozygous; XmnI, Gc-globin promoter 158 (C>T) XmnI polymorphism.
Table 3. Frequency of XmnI polymorphism in heterozygous BT.
Genotype XmnI / XmnI +/ XmnI +/+ Total
Fr 8-9 29 (29%) 5 (5%) 2 (2%) 36 (36%)
IVS 1–5 23 (23%) 5 (5%) 2 (2%) 30 (30%)
Fr 41-42 8 (8%) 0 0 8 (8%)
Cap +1 5 (5%) 0 0 5 (5%)
Fr 16 2 (2%) 0 0 2 (2%)
Cd 5 5 (5%) 1 (1%) 3 (3%) 9 (9%)
Cd 15 4 (4%) 4 (4%) 0 8 (8%)
Cd 30 1 (1%) 0 1 (1%) 2 (2%)
Total 77 (77%) 15 (15%) 8 (8%) 100
BT, Beta thalassaemia; XmnI: Gc-globin promoter 158 (C>T) XmnI polymorphism.
XMNI POLYMORPHISM IN BETA THALASSAEMIA PATIENTS original research reportgenotype was IVSI-5/IVSI-5; 4/26 (15%) cases with
this genotype had XmnI polymorphism. The geno-
types of homozygous/compound heterozygous beta
thalassaemia and XmnI polymorphism detected with
each type are summarised in Table 2. In the heterozy-
gous BT group, Fr 8-9(36%), followed by IVSI-
5(30%), were the most common mutations. XmnI
polymorphism was detected in 23/100(23%) cases
of this group; 70% of XmnI polymorphism (16/23)
was associated with bo phenotype. IVSI-5, followed
by Fr 8-9, were the most common genotypes associ-
ated with XmnI polymorphism (23% and 19% respec-Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015tively). The genotypes of heterozygous BT and XmnI
polymorphism detected with each type are summa-
rised in Table 3.DISCUSSION
Beta thalassaemia is a major health burden in Paki-
stan. Despite preventive measures, around 5000 chil-
dren with transfusion dependent TI or TM are
annually added to the registry. No permanent cure
is available, except stem cell transplantation, which
is unaffordable due to high cost. The majority of13
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patients with transfusion-dependent thalassaemia
have no choice but to have regular blood transfusions
and iron chelation therapy. Haemoglobin F augmen-
tation through HU therapy is another ray of hope
to avoid blood transfusions and associated complica-
tions.13–15 The response to HU therapy has been cor-
related with certain BT genotypes and XmnI
polymorphism. However, this association has not
been well established.9,16
XmnI polymorphism is heterogeneously distrib-
uted in different parts of the world. Our study was
performed in northern Pakistan where Punjabi and
Pathan populations dominate. We found XmnI poly-
morphism in 13% of patients with TM and TI. In a
study by Ansari et al. performed in southern Pakistan
among a dominant Sindhi and Indian migrant popu-
lation, XmnI polymorphism was detected in 45% of
patients.17 XmnI polymorphism was detected in
18–33% of patients with BT in India, in 39–71%
of patients in Iran, 7% in Turkey, and 4% of BT
patients in Egypt.11,18–22 Such a wide variation can
only be explained on the basis of the genetic distribu-
tion of polymorphism, unrelated to the type of BT
mutations, though frequently related to BT geno-
types. The molecular mechanisms describing BT
mutation effects on the distribution of XmnI poly-
morphism are not well outlined. XmnI polymorphism
may also be associated with a completely deleted b-
gene as in the case of db thalassaemia where it can
be assumed that the loss of regulatory regions for
the c-genes, the rearrangement of the b-gene complex
that brings enhancer sequences close to the Gc-globin
gene promoter, and the loss of competition for a com-
mon locus control region (LCR) between the c-, d-,
and the b-gene promoters may be involved.23 No such
association of speciﬁc BT mutations with XmnI poly-
morphism has been described.
XmnI polymorphism was equally distributed in
bo/bo (5/14, 35.5%), and in b+/b+ (5/14, 35.5%)
phenotypes. In the heterozygous BT group, 70% of
XmnI polymorphism was associated with bo pheno-
type, which agrees with studies carried out in India
and Turkey.10,21 It can be inferred that there is a
selective effect of genotypes with the distribution of
XmnI polymorphism, which varies from region to
region. It was also observed that IVSI-5/IVSI-5
could possibly be a genotype that is associated with
XmnI polymorphism, and hence can predict better
response to HU therapy, if XmnI polymorphism is
taken as the major determinant. In the Beta thallasa-emia trait group, 23% of IVSI-5 genotype had XmnI
polymorphism, which further supports the impor-
tance of this genotype. Internationally, other studies
also show an association of XmnI polymorphism with
speciﬁc genotypes like IVS 1-1 (Gﬁ T) in India,
IVS II-1(G > A) in Turkey, and frame shift codon
8 (-AA) in Morocco.11,21,24
In our study, the most common BT genotype was
Fr 8-9/Fr 8-9, and none of the patients with this
genotype had XmnI polymorphism. The second most
common genotype was IVSI-5/IVSI-5, and 15% of
patients with this genotype had XmnI polymorphism.
Overall, the distribution of XmnI polymorphism var-
ied with the genotype. It was more common when
both of the alleles were normal, and was detected in
36/192 normal chromosomes, 31/200 chromosomes
in the heterozygous BT group, and 23/214 chromo-
somes in the homozygous BT group. Our ﬁndings
differ from the ﬁndings of the study performed in
Turkey by Bahader and Atalay, who found XmnI
polymorphism in 43/200 normal chromosomes, 37/
210 with heterozygous BT, and 4/54 chromosomes
of homozygous BT 21. It can be inferred that the dis-
tribution and frequency of XmnI polymorphism dif-
fers greatly among regions, as seen in Iran, India,
and southern Pakistan. Northern Pakistan has a low
frequency of this important determinant of response
to HU therapy.5,6,11,16–19 However, many studies
did not ﬁnd a signiﬁcant correlation of response to
HU with XmnI polymorphism or BT genotype; addi-
tional factors may affect the response to HU therapy
or amelioration of the BT phenotype.7,9,10,14,25 It
should be noted that beta thalassaemia is heteroge-
neous in genetic defects, clinical presentation, and
response to therapy. Further clinical studies based
on response to HU therapy are strongly recom-
mended in this part of the country.
Limitations of study
The study did not cover the genotype/phenotype cor-
relation of BTM and TI patients, correlation of geno-
type with basal HbF levels, or age of ﬁrst transfusion
in BTM/TI patients.CONCLUSION
XmnI polymorphism in homozygous/compound het-
erozygous BT group is 13%. The most common geno-
type associated with XmnI polymorphism is IVSI-5/
IVSI-5.Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
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